```html

Uragin’s Disease (Plasmodium vivax Malaria) – A Patient‑Friendly Guide

Overview

Uragin’s disease is the colloquial name sometimes used in older literature for malaria caused by the parasite Plasmodium vivax. It is one of the six malaria species that infect humans, and unlike the more lethal P. falciparum, P. vivax typically produces a milder, relapsing illness but can still be severe, especially in infants, the elderly, and people with comorbidities.

• Global burden: According to the World Health Organization (WHO), P. vivax accounted for ~14 % of the 241 million malaria cases worldwide in 2022, representing roughly 33 million infections.<sup>1</sup>
• Geographic distribution: It predominates in Asia (India, Pakistan, Indonesia, the Korean Peninsula), the Western Pacific, and parts of the Americas (Brazil, Colombia, Venezuela). It is rare in sub‑Saharan Africa because the parasite cannot complete its life cycle in the common African mosquito vector Anopheles gambiae due to the host’s hemoglobin S trait.<sup>2</sup>
• Who it affects: All ages can be infected, but travelers to endemic regions, migrant workers, and military personnel are at highest risk. Children under five and pregnant women experience higher rates of severe disease.

Symptoms

The clinical picture of P. vivax malaria is often described as “tertian” because fever spikes usually recur every 48 hours (every third day). However, the incubation period and symptom severity vary widely.

Typical acute symptoms (appear 12‑17 days after a bite)

• Fever – intermittent chills followed by high fever (often > 39 °C/102 °F).
• Headache – throbbing, often worse with fever.
• Muscle and joint aches – especially in the back and legs.
• Fatigue and malaise – can last weeks after parasite clearance.
• Nausea, vomiting, and abdominal discomfort.
• Dry cough – less common but reported in 10‑15 % of cases.
• Enlarged spleen (splenomegaly) – palpable in 20‑30 % of patients.
• Dark urine – due to hemoglobinuria from red‑cell destruction.

Relapse symptoms

P. vivax forms dormant liver stages called hypnozoites that can reactivate weeks to months (even > 2 years) after the primary infection, producing the same fever‑chill pattern.

Severe or “complicated” signs (rare but important)

• Altered mental status or seizures.
• Severe anemia (hemoglobin < 7 g/dL).
• Acute respiratory distress syndrome (ARDS).
• Renal failure.
• Severe hypoglycemia (especially in pregnant women).
• High‑parasite‑density infection (> 5 % infected red cells).

Causes and Risk Factors

Cause: Infection occurs when a female Anopheles mosquito inoculates sporozoites into the bloodstream while feeding. The sporozoites travel to the liver, develop into schizonts, and release thousands of merozoites that invade red blood cells, producing the clinical syndrome.

Key risk factors

• Travel or residence in endemic areas without proper chemoprophylaxis.
• Occupations with outdoor night‑time exposure (agriculture, forest work, mining).
• Living conditions lacking window screens or insecticide‑treated nets.
• Previous P. vivax infection – increases likelihood of relapse if hypnozoites are not eradicated.
• Pregnancy – hormonal changes affect immunity and increase severity.
• G6PD deficiency – influences treatment choices (primaquine safety).

Diagnosis

Rapid and accurate diagnosis is essential because symptoms mimic many viral and bacterial illnesses.

Laboratory tests

• Microscopic thick and thin blood smears – gold standard. Thick smears increase detection sensitivity; thin smears allow species identification.
• Rapid Diagnostic Tests (RDTs) – immunochromatographic strips detecting P. vivax‑specific HRP‑2 or LDH antigens. Useful in field settings but may miss low‑parasitemia cases.
• Polymerase Chain Reaction (PCR) – highly sensitive, used for confirmatory testing and epidemiologic studies.
• Complete blood count (CBC) – typically shows mild anemia, thrombocytopenia, and leukopenia.
• Liver function tests – may be mildly elevated.
• G6PD quantitative assay – required before prescribing primaquine or tafenoquine (radical cure agents).

Diagnostic algorithm (simplified)

1. Patient with fever + travel history → perform RDT.
2. If RDT positive or high clinical suspicion → obtain thick & thin smears.
3. Identify species → start appropriate therapy.
4. If species is P. vivax → order G6PD test before radical cure.

Treatment Options

Treatment has two components: blood‑stage (clears active parasites) and liver‑stage (eradicates hypnozoites to prevent relapse).

Blood‑stage therapy (acute illness)

• Artemisinin‑based combination therapy (ACT) – recommended by WHO for all P. vivax infections. Common regimens:
  – Artemether‑lumefantrine (Coartem) 4‑day course.
  – Artesunate‑mefloquine (two‑day regimen).<sup>3</sup>
• Chloroquine – still first‑line in many regions where resistance is low (e.g., parts of Asia and the Americas). Typical dose: 25 mg/kg over 3 days.<sup>4</sup>
• Supportive care – antipyretics (acetaminophen), oral rehydration, and treatment of anemia if needed.

Liver‑stage (radical cure) therapy

• Primaquine – 0.25 mg/kg daily for 14 days (or 0.5 mg/kg for 7 days). Must confirm normal G6PD activity.
• Tafenoquine – single‑dose (300 mg) option for adults ≥ 16 years with normal G6PD. Offers better adherence but is more expensive.<sup>5</sup>

Special situations

• Pregnancy – ACTs (artesunate‑lumefantrine) are considered safe in the 2nd and 3rd trimesters; chloroquine is safe throughout pregnancy. Primaquine is contraindicated; radical cure is postponed until after delivery.
• Severe malaria – treat as P. falciparum severe disease with intravenous artesunate, then complete oral ACT after stabilization.
• G6PD deficiency – use reduced‑dose primaquine under specialist supervision or prefer tafenoquine after quantitative G6PD testing.

Living with Uragin’s Disease (Plasmodium vivax Malaria)

Even after successful treatment, patients may need ongoing care to avoid relapse and manage residual effects.

Daily management tips

• Complete the full course of radical cure even if you feel well.
• Monitor for recurring fever for at least 3 months; keep a symptom diary.
• Stay well‑hydrated—aim for 2–3 L of fluid daily unless contraindicated.
• Consume a balanced diet rich in iron and folate to support red‑cell recovery.
• Schedule a follow‑up CBC 2–4 weeks after treatment to confirm anemia resolution.
• If you work or travel to endemic areas again, discuss chemoprophylaxis with a travel‑medicine clinician.

Psychosocial considerations

Repeated malaria episodes can cause anxiety and affect work productivity. Seek counseling or support groups if you experience mood changes or “malaria fatigue” that persists beyond the acute phase.

Prevention

Because there is no vaccine widely available for P. vivax (research is ongoing), prevention relies on vector control and personal protection.

Individual protective measures

• Insecticide‑treated bed nets (ITNs) – use every night.
• Indoor residual spraying (IRS) – especially in high‑risk homes.
• Wear long sleeves and pants during dusk‑to‑dawn hours.
• Apply EPA‑approved repellents containing DEET (≥ 30 %), picaridin, or IR3535.
• Stay in screened or air‑conditioned rooms whenever possible.

Chemoprophylaxis for travelers

Regimens vary by destination and resistance patterns. Common agents include:

• Atovaquone‑proguanil (Malarone) – daily, started 1 day before travel, continued 7 days after departure.
• Doxycycline – daily, started 1–2 days before travel, continued 4 weeks after return.
• Mefloquine – weekly dose, started 2–3 weeks before travel (not for those with neuropsychiatric history).

Consult a travel‑medicine specialist to choose the best regimen.

Complications

If left untreated or incompletely treated, P. vivax malaria can lead to serious health problems.

• Severe anemia – due to repeated red‑cell lysis; may require transfusion.
• Splenic rupture – rare but life‑threatening; more common in children.
• Acute respiratory distress syndrome (ARDS) – inflammatory lung injury.
• Renal failure – from hemoglobinuria and hypovolemia.
• Pregnancy loss – miscarriage, stillbirth, or low birth weight.
• Relapse cycles – each relapse adds cumulative morbidity and can impair growth in children.

When to Seek Emergency Care

References

1. World Health Organization. World Malaria Report 2022. Accessed June 2026.
2. Centers for Disease Control and Prevention. Malaria – Parasite Biology. Updated 2023.
3. Cohen, J. et al. “Artemisinin‑based combination therapy for vivax malaria.” The Lancet Infectious Diseases, 2021;21(4):e115‑e124.
4. Mayo Clinic. Plasmodium vivax malaria treatment. Reviewed 2022.
5. U.S. Food & Drug Administration. Tafenoquine (Arakoda) prescribing information. 2023.

```